Access cutting-edge acute myelogenous leukemia treatment through this clinical trial at a research site in Omaha. Study-provided care at no cost to qualified participants.
Access acute myelogenous leukemia specialists in Omaha at no cost
This study follows strict safety protocols and ethical guidelines
All study-related acute myelogenous leukemia treatment provided free
This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with AML or higher- risk Myelodysplastic Syndrome (hrMDS). Patients enrolling in the Phase 1 dose escalation of the study must meet one of the following criteria prior to consenting to the study: * Relapse/refractory (R/R) AML with FMS-like tyrosine kinase-3 (FLT3) mutations who have been previously treated with a FLT3 inhibitor * R/R AML
Sponsor: Curis, Inc.
Check if you qualify for this acute myelogenous leukemia clinical trial in Omaha, NE
If you're searching for acute myelogenous leukemia treatment options in Omaha, NE, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Omaha research site is actively enrolling participants for this clinical trial. You'll receive care from experienced acute myelogenous leukemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.